Abstract
Abstract
Purpose
Gemtuzumab ozogamicin (GO) is indicated for treatment of relapsed/refractory (R/R) acute myeloid leukemia (AML). The QT interval, pharmacokinetics (PK), and immunogenicity following the fractionated GO dosing regimen have not been previously assessed. This phase IV study was designed to obtain this information in patients with R/R AML.
Methods
Patients aged ≥ 18 years with R/R AML received the fractionated dosing regimen of GO 3 mg/m2 on Days 1, 4, and 7 of each cycle, up to 2 cycles. The primary endpoint was mean change from baseline in QT interval corrected for heart rate (QTc).
Results
Fifty patients received ≥ 1 dose of GO during Cycle 1. The upper limit of the 2-sided 90% confidence interval for least squares mean differences in QTc using Fridericia’s formula (QTcF) was < 10 ms for all time points during Cycle 1. No patients had a post-baseline QTcF > 480 ms or a change from baseline > 60 ms. Treatment-emergent adverse events (TEAEs) occurred in 98% of patients; 54% were grade 3–4. The most common grade 3–4 TEAEs were febrile neutropenia (36%) and thrombocytopenia (18%). The PK profiles of both conjugated and unconjugated calicheamicin mirror that of total hP67.6 antibody. The incidence of antidrug antibodies (ADAs) and neutralizing antibodies was 12% and 2%, respectively.
Conclusion
Fractionated GO dosing regimen (3 mg/m2/dose) is not predicted to pose a clinically significant safety risk for QT interval prolongation in patients with R/R AML. TEAEs are consistent with GO’s known safety profile, and ADA presence appears unassociated with potential safety issues.
Trial registry
Clinicaltrials.gov ID: NCT03727750 (November 1, 2018).
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Cancer Research,Pharmacology,Toxicology,Oncology
Reference16 articles.
1. Ali S, Dunmore HM, Karres D, Hay JL, Salmonsson T, Gisselbrecht C, Sarac SB, Bjerrum OW, Hovgaard D, Barbachano Y (2019) The EMA review of mylotarg (gemtuzumab ozogamicin) for the treatment of acute myeloid leukemia. Oncologist 24:e171–e179. https://doi.org/10.1634/theoncologist.2019-0025
2. Baron J, Wang ES (2018) Gemtuzumab ozogamicin for the treatment of acute myeloid leukemia. Expert Rev Clin Pharmacol 11:549–559. https://doi.org/10.1080/17512433.2018.1478725
3. Kumar CC (2011) Genetic abnormalities and challenges in the treatment of acute myeloid leukemia. Genes Cancer 2:95–107. https://doi.org/10.1177/1947601911408076
4. Linenberger ML (2005) CD33-directed therapy with gemtuzumab ozogamicin in acute myeloid leukemia: progress in understanding cytotoxicity and potential mechanisms of drug resistance. Leukemia 19:176–182. https://doi.org/10.1038/sj.leu.2403598
5. Pfizer, Inc. (2017) MYLOTARGTM (gemtuzumab ozogamicin) for injection, for intravenous use, US highlights of prescribing information. US Food and Drug Administration. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761060lbl.pdf. Accessed 27 Sep 2022